Physician profile
Ling Li
NPI 1255652053
$2,863.90
in general payments reported to CMS, 2019-2025
41 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $65.94 · 2021: $330 · 2022: $440 · 2023: $907 · 2024: $411 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $399.49 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $283.57 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $255.14 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $172.20 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Abbvie INC. | $156.41 | 2021-2025 | |
| Janssen Biotech, INC. | $144.42 | 2023 | Erleada, Imbruvica, Darzalex |
| Pfizer INC. | $129.43 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $123.10 | 2023 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $114.59 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $114.53 | 2019-2022 | |
| Glaxosmithkline, LLC. | $109.46 | 2019-2023 | Shingrix |
| Applied Medical Resources Corporation | $101.64 | 2024 | |
| Eisai INC. | $60.53 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.64 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.66 | 2023 | Ninlaro, Iclusig |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ling Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.